<DOC>
	<DOCNO>NCT00576303</DOCNO>
	<brief_summary>This single arm study ass efficacy , safety tolerability monthly intravenous Mircera maintenance hemoglobin level dialysis patient chronic renal disease , currently receive epoetin alfa beta . Patients receive monthly intravenous injection Mircera start dose 120 , 200 360 micrograms/month , depend dose epoetin alfa beta receive week precede study start . The anticipated time study treatment 3-12 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Intravenous Mircera Dialysis Patients With Chronic Renal Disease Anemia .</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; chronic renal anemia ; hemodialysis peritoneal dialysis , mode dialysis &gt; =3 month throughout screen period ; continuous maintenance epoetin alfa beta therapy dose interval previous 2 month . transfusion red blood cell previous 2 month ; poorly control hypertension require interruption epoetin alfa beta treatment past 6 month ; significant acute chronic bleed overt gastrointestinal bleeding ; hemolysis ; folic acid vitamin B12 deficiency .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>